These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30323643)

  • 1. Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2018; 11():381-389. PubMed ID: 30323643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2017; 10():47-56. PubMed ID: 28255251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
    Kukulka M; Nudurupati S; Perez MC
    Therap Adv Gastroenterol; 2016 Nov; 9(6):770-780. PubMed ID: 27803732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.
    Kukulka M; Nudurupati S; Perez MC
    Therap Adv Gastroenterol; 2016 Nov; 9(6):759-769. PubMed ID: 27803731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
    Undre N; Dickinson J
    BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing.
    Sostek MB; Chen Y; Skammer W; Winter H; Zhao J; Andersson T
    Aliment Pharmacol Ther; 2003 Sep; 18(6):581-6. PubMed ID: 12969084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
    Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
    Thyssen A; Solanki B; Treem W
    Clin Ther; 2012 Jul; 34(7):1636-45. PubMed ID: 22748970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
    Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
    Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
    Dodds Ashley ES; Varkey JB; Krishna G; Vickery D; Ma L; Yu X; Malavade D; Goodwin M; Perfect JR; Power E
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2960-4. PubMed ID: 19433558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
    Duchin K; Duggal A; Atiee GJ; Kidokoro M; Takatani T; Shipitofsky NL; He L; Zhang G; Kakkar T
    Clin Pharmacokinet; 2018 Feb; 57(2):221-228. PubMed ID: 28512699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Bioavailability of Cenobamate Administered as a Crushed Tablet, Either Orally or via Nasogastric Tube, versus an Intact Whole Tablet.
    Vashi V; Laramy J; Kamin M; Ferrari L; Hand A
    J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38683027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.
    Kukulka M; Eisenberg C; Nudurupati S
    Clin Exp Gastroenterol; 2011; 4():213-20. PubMed ID: 22016582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
    Lee RD; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence among three methods of administering pantoprazole granules in healthy subjects.
    Tammara B; Weisel K; Katz A; Meng X
    Am J Health Syst Pharm; 2009 Nov; 66(21):1923-8. PubMed ID: 19850786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.